News Releases
Committee Recommends Sandoz Cancer Treatment for FDA Approval
Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its investigational biosimilar filgrastim in the US.
Pfizer Announces Palbociclib PALOMA-1 Data Published in The Lancet Oncology
Pfizer Inc. (NYSE:PFE) today announced the publication of the detailed results from PALOMA-1, a randomized Phase 2 study of palbociclib in combination with letrozole versus letrozole alone, in The Lancet Oncology .
Breast Cancer Rx Tested in Phase I Trial
Researchers are constantly testing new medications for various conditions and breast cancer is no exception.
Palbociclib Receives FDA Breakthrough Therapy Designation
Pfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for the potential treatment of patients with breast cancer.